These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15563356)

  • 1. Risk:benefit assessment of old medicines.
    Garattini S; Bertelé V
    Br J Clin Pharmacol; 2004 Dec; 58(6):581-6. PubMed ID: 15563356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazide diuretics in the treatment of hypertension: an update.
    Salvetti A; Ghiadoni L
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S25-9. PubMed ID: 16565243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manufacturing uncertainty: adverse effects of drug development for women.
    Peppin P
    Int J Law Psychiatry; 2003; 26(5):515-32. PubMed ID: 14522223
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
    Serebruany V
    Thromb Haemost; 2010 Feb; 103(2):415-8. PubMed ID: 20126838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive approach to benefit-risk assessment in drug development.
    Sarac SB; Rasmussen CH; Rasmussen MA; Hallgreen CE; Søeborg T; Colding-Jørgensen M; Christensen PK; Thirstrup S; Mosekilde E
    Basic Clin Pharmacol Toxicol; 2012 Jul; 111(1):65-72. PubMed ID: 22356197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect comparisons in the comparative efficacy and non-inferiority settings.
    Snapinn S; Jiang Q
    Pharm Stat; 2011; 10(5):420-6. PubMed ID: 21956948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis.
    Casella G; Ottani F; Pavesi PC; Sangiorgio P; Rubboli A; Galvani M; Fontanelli A; Bracchetti D
    Ital Heart J; 2003 Oct; 4(10):677-84. PubMed ID: 14664280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel: new preparation. An alternative to aspirin.
    Prescrire Int; 1999 Dec; 8(44):163-4. PubMed ID: 11503810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified.
    Serebruany VL
    Thromb Haemost; 2011 May; 105(5):752-9. PubMed ID: 21384079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-risk assessment: to quantify or not to quantify, that is the question.
    Yuan Z; Levitan B; Berlin JA
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
    [No Abstract]   [Full Text] [Related]  

  • 13. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Success rates for new drugs entering clinical testing in the United States.
    DiMasi JA
    Clin Pharmacol Ther; 1995 Jul; 58(1):1-14. PubMed ID: 7628176
    [No Abstract]   [Full Text] [Related]  

  • 15. Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning.
    Friedman JH
    Neurology; 2006 Aug; 67(4):564-6. PubMed ID: 16924004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance.
    Jennings LK
    Crit Pathw Cardiol; 2009 Mar; 8(1):20-8. PubMed ID: 19258834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ACCOMPLISH and the risks with company sponsored clinical trials].
    Furberg C
    Lakartidningen; 2009 Feb 11-17; 106(7):450. PubMed ID: 19350775
    [No Abstract]   [Full Text] [Related]  

  • 18. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part I: Concept of resistance.
    Vadász D; Sztriha LK; Sas K; Vecsei L
    Ideggyogy Sz; 2012 Nov; 65(11-12):377-85. PubMed ID: 23289172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.